Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Crispr Therapeutics AG (CRSP) vs Dow Inc (DOW) Price & Performance

Crispr Therapeutics AGTrade

Price performance (Past 24H)

Key statistics

Crispr Therapeutics AG vs Dow Inc — how do they compare? Crispr Therapeutics AG trades at $53.9 (market cap $5.23B), while Dow Inc trades at $31.24 (market cap $22.58B). The key difference: Dow Inc is far larger — about 4.3× Crispr Therapeutics AG's market cap, and Dow Inc pays a 4.48% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.

CRSPDOW
Market Cap
$5.23B$22.58B
Sector
HealthBasic Materials
52-Week High
$76.78$41.87
52-Week Low
$44.34$20.65
Enterprise Value
$3.65B$38.27B
Dividend Yield
4.48%

Returns comparison

Trailing returns across standard periods

About Crispr Therapeutics AG

CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.

Read more on CRSP

About Dow Inc

Dow Inc is a diversified chemical manufacturing company. It combining science and technology to develop innovative solutions that are essential to human progress. Dow's portfolio is comprised of six global business units, organized into three operating segments: Packaging & Specialty Plastics, Industrial Intermediates & Infrastructure, and Performance Materials & Coatings.

Read more on DOW